Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

• Annemiek Broijl,
• Marie-José Kersten,
• Wendimagegn Ghidey Alemayehu,
• Mark-David Levin,
• Okke de Weerdt,
• Edo Vellenga,
• Ellen Meijer,
• Shulamit Wittebol,
• Bea C. Tanis,
• Petra B. Cornelisse,
• Marian Stevens-Kroef,
• Gerard M.J. Bos,
• Pierre W. Wijermans,
• Henk Lokhorst,
• Pieter Sonneveld

Affiliations

Annemiek Broijl

Department of Hematology, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands

Marie-José Kersten

Department of Hematology, Academic Medical Center (AMC), Amsterdam, the Netherlands

Wendimagegn Ghidey Alemayehu

HOVON Data Center, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands

Mark-David Levin

Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands

Okke de Weerdt

Department of Hematology, Antonius Hospital, Nieuwegein, the Netherlands

Edo Vellenga

Department of Hematology, University Medical Center (UMCG), Groninge, the Netherlands

Ellen Meijer

Department of Hematology, VU medical center, Amsterdam (VUmc), the Netherlands

Shulamit Wittebol

Department of Hematology, Meander Medical Center, Amersfoort, the Netherlands

Bea C. Tanis

Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, the Netherlands

Petra B. Cornelisse

HOVON Data Center, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands

Marian Stevens-Kroef

Working group on Hemato-Oncologic Genome Diagnostics (WHGD), Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands

Gerard M.J. Bos

Department of Hematology, University Hospital, Maastricht, the Netherlands

Pierre W. Wijermans

Department of Hematology, HAGA Hospital, the Hague, the Netherlands

Henk Lokhorst

Department of Hematology, VU medical center, Amsterdam (VUmc), the Netherlands

Pieter Sonneveld

Department of Hematology, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands